Ferronova is an Adelaide-based medical technology company developing a super-paramagnetic iron oxide nanoparticle tracer system designed to improve image-guided cancer surgery. The nanoparticles bind to lymph-node cells, allowing surgeons to identify tissue that may harbour metastasised cancer and thereby reduce post-operative recurrence. The company is running a 60-patient, two-year clinical trial on stomach and oesophageal cancers at leading Australian centres, having enrolled 54 patients with completion expected in early 2026. Management plans to extend research to the United States over the next two years as it moves toward regulatory approval and commercial launch. Roughly 1.8 million people are diagnosed with stomach and oesophageal cancers annually, underscoring the market need the firm targets. Ferronova has raised a cumulative $17.5 million in Series A funding, giving it capital to complete trials and pursue commercialisation. Its investor base includes Uniseed/UniSuper, South Australian Venture Capital Fund, Artesian Venture Partners, Renew Pharmaceuticals (UltraGreen.ai), several universities, and health-focused funds. The company’s mission is to enhance surgical precision and improve survival rates in complex, early-stage cancers.

Total raised

$17M

Funding rounds

4

Latest round

Series A

Latest activity

Dec 2025